Its receptor, VEGFR2, is expressed selectively in intra-tumor Treg cells with high expression of Foxp3 (Figure 3A) [101], and it is proposed that both VEGFR2 and Foxp3 may be better predictive markers for recurrence and survival in patients with CRC [101]. Here, FOXP3 is linked to neoplasm.